Cargando…
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM
INTRODUCTION: Multiple sclerosis (MS) clinical trials have included low numbers of patients from racial and ethnic minority populations; therefore, it is uncertain whether differences exist in response to disease-modifying therapies. We evaluated the real-world safety and effectiveness of dimethyl f...
Autores principales: | Williams, Mitzi J., Amezcua, Lilyana, Chinea, Angel, Cohan, Stanley, Okai, Annette, Okuda, Darin T., Vargas, Wendy, Belviso, Nick, Božin, Ivan, Jiang, Xiaotong, Lewin, James B., Lyons, Jennifer, Shen, Changyu, England, Sarah M., Grimes, Nydjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444730/ https://www.ncbi.nlm.nih.gov/pubmed/37354276 http://dx.doi.org/10.1007/s40120-023-00517-1 |
Ejemplares similares
-
Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Chinea, Angel, et al.
Publicado: (2020) -
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM
por: Williams, Mitzi J., et al.
Publicado: (2020) -
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
por: Amezcua, Lilyana, et al.
Publicado: (2023) -
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation
por: Wright, Katy, et al.
Publicado: (2017) -
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
por: Okai, Annette F., et al.
Publicado: (2019)